This observational study aimed to ascertain the prevalence of PIK3CA mutations in patients with metastatic HR+/HER2– BC in Bulgaria, as well the evaluation and comparison of PFS between WT and mutant cohorts in the real world. The gene discussed is ERBB2; the disease is breast cancer.